Boston Deferred Long Term Liab from 2010 to 2025

BSX Stock  USD 100.80  1.54  1.50%   
Boston Scientific Deferred Long Term Liabilities yearly trend continues to be fairly stable with very little volatility. Deferred Long Term Liabilities will likely drop to about 123.1 M in 2025. Deferred Long Term Liabilities is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. View All Fundamentals
 
Deferred Long Term Liabilities  
First Reported
2009-06-30
Previous Quarter
210 M
Current Value
135 M
Quarterly Volatility
737 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Boston Scientific financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Boston Scientific's main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.4 B, Interest Expense of 198.1 M or Selling General Administrative of 6.3 B, as well as many indicators such as Price To Sales Ratio of 4.7, Dividend Yield of 4.0E-4 or PTB Ratio of 5.9. Boston financial statements analysis is a perfect complement when working with Boston Scientific Valuation or Volatility modules.
  
Check out the analysis of Boston Scientific Correlation against competitors.

Latest Boston Scientific's Deferred Long Term Liab Growth Pattern

Below is the plot of the Deferred Long Term Liab of Boston Scientific Corp over the last few years. It is liabilities that are due after more than one year, including deferred tax liabilities and deferred revenue. Boston Scientific's Deferred Long Term Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Boston Scientific's overall financial position and show how it may be relating to other accounts over time.
Deferred Long Term Liab10 Years Trend
Slightly volatile
   Deferred Long Term Liab   
       Timeline  

Boston Deferred Long Term Liab Regression Statistics

Arithmetic Mean607,170,000
Geometric Mean0.00
Coefficient Of Variation111.06
Mean Deviation545,768,750
Median328,000,000
Standard Deviation674,319,121
Sample Variance454706.3T
Range1.9B
R-Value(0.74)
Mean Square Error220286.6T
R-Squared0.55
Significance0
Slope(104,832,941)
Total Sum of Squares6820594.2T

Boston Deferred Long Term Liab History

2025123.1 M
2024129.6 M
2022144 M
2021310 M
2020330 M
2019595 M
2018328 M

About Boston Scientific Financial Statements

Boston Scientific investors use historical fundamental indicators, such as Boston Scientific's Deferred Long Term Liab, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Boston Scientific. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Deferred Long Term Liabilities129.6 M123.1 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Boston Stock Analysis

When running Boston Scientific's price analysis, check to measure Boston Scientific's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Boston Scientific is operating at the current time. Most of Boston Scientific's value examination focuses on studying past and present price action to predict the probability of Boston Scientific's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Boston Scientific's price. Additionally, you may evaluate how the addition of Boston Scientific to your portfolios can decrease your overall portfolio volatility.